Kass: How to Short

Editor's note: These posts by Doug Kass are a special bonus for TheStreet.com and RealMoney readers. They first appeared on Street Insight on March 30. To sign up for Street Insight, where you can read Kass' commentary in real time, please click here.

As a dedicated short-seller, I incorporate some basic tenets and disciplines in my portfolio management.

One of those principles is to avoid hard-to-borrow and heavily shorted stocks.

Yesterday, Dendreon (DNDN Quote) announced that the Food and Drug Administration said its Provenge drug (the first active cellular immunotherapy and the first biologic approved to treat prostate cancer) was safe and that there was "substantial evidence of efficacy." ...